Philippe Pinton

Philippe Pinton has a diverse and extensive work experience spanning over several industries. Their most recent role is as a Member of the Board of Directors at PharmaBiome AG, a company specializing in intestinal bacteria and the production of function-based defined consortia. Philippe is also the Chief Executive Officer and Co-Founder of a company called シロイト株式会社.

Previously, Pinton held several leadership positions at Ferring Pharmaceuticals, where they played a key role in developing and executing patient-centric Research & Development strategies. Philippe was the Senior Vice President, Global Head of Clinical and Translational Sciences, Senior Vice President, Global Head of Translational and Clinical R&D, and Vice President, Global Head of Translational Medicine & Clinical Pharmacology.

Before joining Ferring Pharmaceuticals, Pinton had leadership roles at Takeda, Celgene, Novartis, and Eli Lilly. At Takeda, they served as the Head of the GI Medical Franchise, Head of the Specialty Medicines Franchise, and Executive Country Medical Director. Philippe was also the Senior Medical Director for Inflammation & Immunology at Celgene and the Franchise Head for Immunology & Dermatology at Novartis.

Pinton's early experience includes founding and being the Chief Executive Officer of Mom'Aï, a leadership consulting company in the pharmaceutical and biotechnology industries. Philippe also held various managerial positions at Eli Lilly, including Head of Cardiovascular Therapeutic Unit, Intercontinental Region, Emerging Markets, Japan, Lean Six Sigma Black Belt Manager, and Head of various medical units.

Prior to their time at Eli Lilly, Pinton was the Head of the Cardiovascular Unit at LEO Pharma A/S.

Philippe Pinton has an extensive education history. Philippe obtained their undergraduate medical education from Université Paris Cité from 1979 to 1986, specializing in medicine. Philippe then pursued a Doctor of Medicine (MD) degree from the University of Lille 1 Sciences and Technology, focusing on medicine, cardiology, and intensive care from 1987 to 1991. Philippe also holds a Master's degree in Pharmacology from the same university. In 1990-1991, they earned another Master's degree, this time in Statistics and Epidemiology from Pierre and Marie Curie University. Philippe furthered their studies at Pierre and Marie Curie University and received a postgraduate diploma in Thrombosis, Pathogenesis, and Treatment from 1991 to 1992.

Additionally, Philippe has pursued education in other areas. Philippe completed a Diploma/Competency program in Civil War and Disaster Medicine from the University of Lille 1 Sciences and Technology in 1994-1995. Philippe also attended several executive programs, including the Global Business Perspectives Executive MBA Major programs at Tsinghua University in 2011 (Doing Business in China) and FGV - Fundação Getulio Vargas in 2011 (Doing Business in Brazil). Philippe obtained an Executive MBA degree with a specialization in Global Business Perspectives from HEC Paris in 2012.

To expand their knowledge and skills, Philippe has pursued various certificates and certifications. Philippe obtained a Certificate in Innovative Leadership in Medical Affairs from Saïd Business School, University of Oxford in 2017. Philippe also completed the Strategy in the Age of Digital Disruption program at INSEAD in 2018. In 2021, Philippe received the Artificial Intelligence in Health Care Certificate from MIT Sloan School of Management.

In addition to their formal education, Philippe has obtained additional certifications. These include an Artificial Intelligence in Healthcare certification from MIT Sloan School of Management in 2021, an Adaptability & Resilience certification from McKinsey & Company in 2021, and a Lean Six Sigma Black Belt Certification in 2005.